Clinical Trial Update: BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating linagliptin (BI 1356) in combination with metformin and a sulphonylurea for type 2 diabetes; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)
• Sulphonylurea (sulphonylurea)
• metformin (metformin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2011-06-15